Tirzepatide |
| Catalog No.GC34840 |
Tirzépatide (LY3298176) est un agoniste double récepteur de polypeptide insulinotrope dépendant du glucose (GIP) et de glucagon-like peptide-1 (GLP-1) qui est en cours de développement pour le traitement du diabète de type 2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2023788-19-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, is a prospective therapy for type 2 diabetes mellitus (T2DM) [1-3].
Tizepatide(0.2 μM;7days) can ameliorate high glucose-induced neurodegeneration and overcome neuronal insulin resistance[4].
Tirzepatide (10 nmol/kg;14days; s.c) remarkably reduces LPS-mediated inflammatory responses by inhibiting the cardiac protein levels of TNF-α, IL-6, and IL-1B in mice[5]. Chronic treatment with tirzepatide(3-10 nmol/kg;14days; s.c) enhanced insulin tolerance in obese mice[6]. Tirzepatide had anti-allergic inflammatory effects for the aeroallergen-induced model in obese asthma[7]. Tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes[8].
References:
[1]. Willard FS, Douros JD, et,al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020 Sep 3;5(17):e140532. doi: 10.1172/jci.insight.140532. PMID: 32730231; PMCID: PMC7526454.
[2]. Coskun T, Sloop KW, et,al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
[3]. Forzano I, Varzideh F, et,al. Tirzepatide: A Systematic Update. Int J Mol Sci. 2022 Nov 23;23(23):14631. doi: 10.3390/ijms232314631. PMID: 36498958; PMCID: PMC9741068.
[4]. Fontanella RA, Ghosh P, et, al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024 Jan 29;22(1):114. doi: 10.1186/s12967-024-04927-z. PMID: 38287296; PMCID: PMC10823712.
[5]. Liu Q, Zhu J, et,al. Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway. Int Immunopharmacol. 2023 Jul;120:110311. doi: 10.1016/j.intimp.2023.110311. Epub 2023 May 15. PMID: 37196559.
[6]. Samms RJ, Christe ME, et,al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021 Jun 15;131(12):e146353. doi: 10.1172/JCI146353. PMID: 34003802; PMCID: PMC8203452.
[7]. Toki S, Zhang J, et,al. Dual GIPR and GLP-1R agonist tirzepatide inhibits aeroallergen-induced allergic airway inflammation in mouse model of obese asthma. Clin Exp Allergy. 2023 Feb;53(2):216-221. doi: 10.1111/cea.14252. Epub 2022 Nov 15. PMID: 36377605; PMCID: PMC10163938.
[8]. Thomas MK, Nikooienejad A, et,al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. doi: 10.1210/clinem/dgaa863. PMID: 33236115; PMCID: PMC7823251.
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *